hotspot -WSS

hotspot

author：hotspot 2025-09-30 17:27:04 - browse：6569

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

hotspot

WSS

First Opinion Podcast: How to protect health care in times of war

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Telehealth options flood the market as retailers push virtual care

CDC recommends rationing of RSV shot due to shortages

NEJM study link tiny plastics in blood vessels to heart problems

First medicine developed to treat MASH expected to be approved soon

hotspot

hotspot

focus

United colonoscopy coverage change 'may cost lives,' doctors say

The problem with charging patients to message their doctors

Medicare proposal to cover medical devices draws a mixed reaction

Testing for cancer recurrence creates a new limbo for patients

Activists slam private health insurers over coverage restrictions

Why Sanofi got shellacked over its spinoff

ChatGPT in medicine: STAT answers readers' burning questions

The drug industry has found itself all alone in Washington

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Wikipedia

IVF, abortion rights issues kick off Biden’s State of the Union

WHO may add ‘noma' to its list of neglected tropical diseases

Change Healthcare cyberattack prompts Medicare loan program

Amylyx ALS drug failure raises questions and concerns

Just how do doctors, lawmakers, and the public define abortion?

RSV shot was 90% effective at preventing hospitalizations in kids

leisure time

leisure time

hotspot

leisure time